Predilife s’introduit sur Euronext Growth


IPO raises €3.6 million; market capitalisation €25.7 million

Paris – 21 December 2018Euronext today welcomed PrediLife, a provider of innovative personalised solutions that analyse and predict the risk of a selection of serious diseases, to its Euronext Growth market.

Founded in 2004 by Stéphane Ragusa, PrediLife combines proven medical techniques (genetic testing, medical imagery, etc.) with mathematical models using a very large amount of statistical data to produce innovative predictive solutions that enable individuals to ascertain their own risk profile for serious diseases. The company markets its MammoRisk® personalised breast cancer screening system in Europe, providing women and medical practitioners with a tool to assess individual risk.

PrediLife (ticker code: ALPRE) was listed on 21 December 2018 through the admission to trading of 2,758,154 shares making up its capital, including 386,154 new shares issued as part of a Global Offering[1]

The offering price was set at €9.30 per share. Market capitalisation on the day of listing was around €25.7 million, and the operation raised a total of €3.6 million.

At the listing ceremony, Stéphane Ragusa, CEO of PrediLife, said: “We are proud to announce our successful listing today on Euronext Growth in Paris, with the arrival of new shareholders whom we would like to thank for their trust. We also want to thank the existing investors that have renewed their support. Funds raised will allow PrediLife to step up the commercial rollout of our MammoRisk® solution in France and on international markets.”


[1] The Global Offering was made up of a Public Offering that included an Open Price Offer (OPO) and a Global Placement with institutional investors in France and other countries.

About PrediLife
PrediLife develops innovative predictive medicine solutions that combine proven medical techniques (genetic testing, medical imaging etc.) with mathematical models using a large amount of statistical data, which potentially allow individuals to ascertain their own risk profile regarding the occurrence of a large number of serious diseases.
The company markets its MammoRisk® personalised breast cancer screening solution in Europe and the United States. This combines medical imaging—from PrediLife’s proprietary DenSeeMammo software for measuring breast density—with Big Data and statistics through a scoring tool that uses patient-related data (age, breast density, family history, biopsy results, ethnic origin) and a study of the patient’s genetic profile through a genetic test, to establish a polygenic risk score. MammoRisk® addresses demand among women and medical practitioners for screening programmes that are personalised to reflect the risk of breast cancer.
PrediLife is in charge of assessing breast cancer risks as part of the European MyPeBS reference study. The study’s main aim is to compare the current screening approach—where age is the only criterion—with a new screening strategy based on each woman’s risk level. Another aim of the MyPeBS study is to produce European guidelines for the introduction of personalised screening.
Personalised screening is likely to have a major impact on public health, initially by reducing the number of cases in which breast cancer is diagnosed only at an advanced stage, and ultimately by reducing the breast cancer mortality rate.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 1,930 listed issuers and around €6.8 trillion in market capitalisation as of end March 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.